ethylestrenol
Trade name: maxibolin
Small moleculeapproved
Approved
May 28, 1964
Ethylestrenol (INN, USAN, BAN) (brand names Maxibolin, Orabolin), or ethylnandrol (JAN), also known as 17α-ethyl ester-4-en-17β-ol or as 3-deketo-17α-ethyl-19-nortestosterone, is an anabolic-androgenic steroid (AAS) with some progestogenic activity, and low androgenic activity. It is a 17α-ethylated derivative of nandrolone and lacks the 3-keto group. It was described in the literature in 1959 and approved in 1964 for testosterone deficiency in male patients. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Approval history
- approvedMay 28, 1964
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@]12C- Mol. weight
- 288.4675 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaEthylestrenol ↗
- NCATSADC79EK5Q8 ↗
- ChEMBLCHEMBL1200623 ↗
Also known as
- estrenolethyl
- ethylestrenol
- ethylestrenol
- ethylestrenol
- ethylestrenol
- ethylestrenol
- ethylestrenol
- ethylestrenol
- ethylestrenol
- ethylnandrol
- ethylnandrol
- ethylnandrol
- ethyloestrenol
- ethyloestrenol
- maxibolin
- maxibolin
- maxibolin
- orabolin
- orabolin
- orabolin
- orabolin
- orabolin
- orabolin
Organizations
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Organon | For profit | NDA | May 28, 1964 |